Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Summary

Despite the clinical success of immune checkpoint blockade (ICB), in neoadjuvant setting, there is still a lack of valid data for operable NSCLC in the real world. This study aim to compare the clinical outcomes (pathologic response rate versus survival) of neoadjuvant immunochemotherapy with neoadjuvant chemotherapy in the real world, to explore the impact of clinicopathological factors on clinical outcomes in neoadjuvant immunochemotherapy setting, and to identify potential neoadjuvant immunochemotherapy beneficiaries.

Eligibility

Inclusion Criteria:

1. Cytological or histological diagnosis of non-small cell lung cancer
2. Patients who have previously undergone neoadjuvant immune checkpoint inhibitors and/or chemotherapy and then undergone radical surgery;
3. Stage I-III non-small cell lung cancer (IASLC/UICC staging eighth edition);
4. No previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment;
5. ECOG score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery;
6. At least one measurable lesion (RECIST v1.1);
7. Age \>= 18 years old and \<= 85 years old;
8. Be able to abide by the visits and related procedures stipulated in the program.

Exclusion Criteria:

1. Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown.
2. Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.

Conditions3

Interventions2

Related trials

• AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy — Chinese Academy of Sciences
• Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy — Assiut University
• Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver — Yunnan Cancer Hospital
• Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC — Obstetrics & Gynecology Hospital of Fudan University
• Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB) — Rajiv Gandhi Cancer Institute & Research Center, India
• Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy — University Hospital, Rouen
• Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) — First Affiliated Hospital of Zhejiang University
• Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer — Xijing Hospital

Browse More Trials